Group 1: Overall Financial Data - In August, the new social financing (社融) amounted to 3.03 trillion yuan, a year-on-year decrease of 98.1 billion yuan, with a growth rate of 8.1%, down 0.1 percentage points from the previous value[1] - The August social financing increment is higher than the average of 2.87 trillion yuan over the past five years[1] - The main contributors to social financing were government bonds and RMB loans, accounting for 53% and 34% of the new social financing, respectively[4] Group 2: Structural Weaknesses - Government bonds increased by 1.61 trillion yuan, a record high for the same period, while RMB loans only increased by 1.04 trillion yuan, the lowest since 2017[1][4] - Excluding government bonds, the social financing growth rate would be 6.48%, reflecting a decline of 0.18 percentage points from July[4] - The proportion of RMB loans in new social financing dropped to 16% when excluding the 545.1 billion yuan in bill financing, which accounted for 52% of RMB credit[1][4] Group 3: Corporate and Household Loans - Corporate medium- and long-term loans decreased by 154.4 billion yuan to 490 billion yuan, the lowest for the same period since 2020, with a growth rate decline of 0.24 percentage points to 12.08%[8] - Household medium- and long-term loan growth rate fell by 0.08 percentage points to 3.95%, with a year-on-year decrease of 40.2 billion yuan, marking the lowest since 2012[8] - In August, corporate deposits increased by only 350 billion yuan, the lowest for the same period since 2015, significantly below the five-year average of 746.6 billion yuan[12] Group 4: Market Implications - The decline in corporate medium- and long-term loan growth is a necessary condition for the sustained rise in interest rates since 2016, indicating that the downward cycle has not yet ended[12] - The current financing demand is weak, and the confidence of microeconomic entities remains insufficient, as reflected in the further decline of M1 growth to -7.3%[12]

huangwz1@essence.com.cn 2024 年 09 月 13 日 透视 A 股：历史的双底 报告摘要： 估值分化指数：上周行业估值分化指数有所下降 全球市场概览：上周 A 股普跌，成交量相较上一周有所上涨 市场风格：上周小盘风格占优 货币市场：上周流动性边际收紧 基金发行：上周发行上升，仓位处历史中位 市场情绪：上周 A 股换手率下降，美国恐慌指数上升 国债及外汇市场：上周国债收益率下降，人民币贬值 资金流向：上周两融余额下降，A 股资金流出 重要股东减持：上周食品饮料减持最多 机构调研：近一个月机构密集调研医药生物行业 出口：7 月船舶出口持续增长 货币供给与社融：7 月 M2 增速上升、社融增速上升 中游景气：7 月居民用电量同比增长 20.8% 风险提示：政策不及预期，地域政治冲突超预期 本报告版权属于国投证券股份有限公司，各项声明请参见报告尾页。 1 相关报告 | --- | --- | |----------------------------------------------------|------------| | | | | 高股息的分化与最优解—— | 2024-09-1 ...

行业深度分析 2024 年 09 月 13 日 有色金属 美国大选对有色金属的影响 美国大选选情持续焦灼 美国大选两党竞争持续焦灼，据 RCP，截至 9 月 4 日，哈里斯支持率 48.3%，领先特朗普 46.5%约 1.8 个百分点，在 8 月 5 日赶超特朗普 且维持优势。7 个摇摆州中，目前特朗普在 2 个州领先，大选选情仍 然焦灼。共和党强调美国优先，特朗普政策的核心是低利率低税率， 更多使用民族主义政策手段，并带有贸易保护主义。民主党强调公平 正义，主张大政府，对富人和大公司征收更高的税收，以减少经济不 平等。 共和党当选提升有色金融属性定价，民主党当选对"新动能" 金属更为利好 美国大选将从 1.金融属性 2.供给 3.需求 4 地缘政治等其他，这 4 个 方面影响到有色金属价格未来走势。 金融属性方面，共和党财政货币双宽松，偏好弱美元，直接利好黄金， 相对利好其他有色金属。民主党在货币政策上相对尊重美联储独立 性，财政政策上以结构性加税为主，但哈里斯新政策下财政收缩程度 有限，通胀相对控制程度或较好，对黄金和铜等有色金属价格影响中 性。 商品属性的需求方面，1）基建：两党均重视基建计划，区别在于 ...

2024 年 09 月 12 日 机械 行业深度分析 2024 中报总结：内需不足竞争加剧，短期业绩承压 我们从本体及系统集成、核心零部件厂商中选取了 31 家机器人板块 重点公司进行分析。①市场表现：主题性明显，受人形机器人事件催 化波动较大。2024 年初至 8 月底整体涨幅-14.05%，弱于同期沪深 300 指数，主要系人形机器人量产规模不及预期等事件影响。②市场需求 偏弱，短期业绩承压。2024H1 样本公司整体收入合计 262.22 亿元， 同比减少 0.01%，归母净利润 15.50 亿元，同比减少 25.97%。受整体 制造业扩张预期下降、市场需求仍有待复苏等影响，机器人本体及系 统集成和特种机器人领域，样本公司收入和利润普遍下滑。核心零部 件领域整体业绩保持增长，但公司间业绩分化较大：1.受益于新能源 汽车产销量较快增长，下游主要为汽车零部件、汽车电子的企业营收 增长较快；2.受光伏、锂电行业去库存和设备行业投资低迷等影响， 下游为新能源、设备行业的企业营收增速较慢或为负值。③毛利率& 费用率提升，盈利端下滑明显：2024H1 板块整体毛利率 25.66%，同 升 0.05pct；期间费用率 ...

Investment Rating - The industry is rated as "Outperforming the Market" with a rating of -A, maintaining the current rating [3] Core Insights - The performance of the brokerage industry is under significant pressure, with a notable decline in revenue and net profit for listed brokerages in the first half of 2024. Total operating revenue reached 240 billion yuan, down 13% year-on-year, while net profit attributable to shareholders was 68 billion yuan, down 21% year-on-year [10][11] - The top five brokerages showed resilience, with a combined operating revenue of 85.3 billion yuan, also down 13% year-on-year, and a net profit of 26.2 billion yuan, down 18% year-on-year. However, major firms like Haitong Securities and CICC experienced significant declines [10][11] Summary by Sections 1. Industry Overview - In the first half of 2024, 44 listed brokerages achieved total operating revenue of 240 billion yuan, a decrease of 13% year-on-year, and a net profit of 68 billion yuan, down 21% year-on-year. The decline is attributed to increased market volatility, a slowdown in IPO activity, and weak fund issuance [10][11] 2. Business Performance 2.1 Brokerage Business - The average daily trading volume for stock-based transactions in the first half of 2024 was 984.6 billion yuan, down 6.8% year-on-year. The brokerage business revenue for 43 brokerages was 45.8 billion yuan, down 13% year-on-year [18][19] - Major brokerages like CITIC, Guotai Junan, and GF Securities experienced smaller declines compared to the industry average, while CICC and Haitong saw more significant drops [19] 2.2 Investment Banking - The investment banking sector faced challenges due to tighter financial regulations, with IPO financing in the first half of 2024 totaling 32.5 billion yuan, down 85% year-on-year. The number of IPOs also decreased by 75% [21][24] - The total investment banking revenue for 43 listed brokerages was 14 billion yuan, down 41% year-on-year, with top firms like CITIC and Haitong experiencing declines exceeding 50% [21][24] 2.3 Credit Business - The average daily margin trading balance was 1.53 trillion yuan, down 3.8% year-on-year. The stock pledge market also saw a decline, with the number of pledged shares reaching 3.417 billion shares, down 7% year-on-year [26] 2.4 Asset Management - The net asset value of bond funds increased by 27% year-on-year, reaching 10.59 trillion yuan, while equity funds saw a decline of 11%, totaling 6.16 trillion yuan. The asset management revenue for listed brokerages was 22.7 billion yuan, down 1% year-on-year [6] 2.5 Proprietary Trading - The proprietary trading income for listed brokerages was 75 billion yuan, down 9% year-on-year, with performance varying significantly among different brokerages [6] 3. Market Outlook - Despite short-term pressures from regulatory tightening and a slowdown in IPOs, there is potential for marginal recovery in brokerage fundamentals in the second half of 2024, driven by improved market confidence and ongoing merger and acquisition activities [7]

2024 年 09 月 11 日 高股息的分化与最优解——基于本轮高股息回调下的基本面解释 在 2024 年 4 月，我们观察到高股息策略领涨本质并不是简单基于看好高股息的 定价（事实上基于低风险偏好最佳手段是降低仓位），而是基于资金视角下的"价 值派抱团"，并提出"凡是趋势皆为抱团"。步入 2024 年 5 月之后，我们预判 以中证红利全收益为代表的高股息策略与 1-4 月大幅上涨的局面可能会发生变 化，中证红利指数波段属性将明显增强，高股息策略波段属性增强背后是相当一 批不能做到稳定持续分红的品种被验伪，而价值派抱团将推动高股息核心品种 进入到泡沫化阶段"，所谓的高股息核心品种是那些基于稳定现金流且 ROE 中 枢上移的分红仍获得追捧（即公用服务：水电+电信服务+高速），并进一步认为 公用事业是高股息的最终胜负手，背后推动力来自主动多头的妥协。 目前来看，截止 2024 年 5 月初各类红利指数表现呈现出同步上涨的趋势，随后 进入到 5 月中旬后开始出现分化，消费、纺服占比较高的深证红利指数率先出 现下跌；进入到 7 月初之后，煤炭景气度开始出现明显下滑，中证红利指数出现 大幅下跌，从 2024 年至今主 ...

公司快报 2024 年 09 月 11 日 美的集团(000333.SZ) 证券研究报告 白色家电Ⅲ 投资评级 买入-A 维持评级 6 个月目标价 80.85 元 股价 (2024-09-10) 60.75 元 交易数据 总市值(百万元) 424,355.41 流通市值(百万元) 417,301.01 总股本(百万股) 6,985.27 流通股本(百万股) 6,869.15 12 个月价格区间 49.18/72.71 元 拟发行 H 股，加速全球化扩张步伐 事件：2024 年 9 月 9 日，公司在香港刊登并派发 H 股招股说明 书。预计公司本次全球发售 H 股股数为 4.9 亿股~ 6.5 亿股，约占 公司当前总股本的 7.0%~9.3%。公司本次 H 股发行的价格区间初 步确定为 52.00 港元~54.80 港元，约为公告前一交易日 （20240906）A 股收盘价的 75%~79%（按照 20240906 港币兑人民 币中间价 1HKD=0.91CNY 计算）。公司 H 股香港公开发售于 2024 年 9 月 9 日开始，预计于 2024 年 9 月 12 日结束，并预计于 2024 年 9 月 13 ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 6.25 CNY for the next six months [3][6]. Core Views - The company's revenue for H1 2024 was 544.52 billion CNY, a year-over-year decrease of 7.83%, with a net profit of 14.28 billion CNY, down 12.08% year-over-year [1][6]. - The infrastructure business is under pressure, while emerging businesses are growing rapidly, and overseas business gross margins are improving [1][2]. - The company has signed new contracts worth 166.33 billion CNY in emerging businesses, a 32.1% increase year-over-year, indicating potential for future profit contributions [2]. Summary by Sections Financial Performance - In H1 2024, the company achieved a revenue of 544.52 billion CNY, with a year-over-year decline of 7.83%. The net profit was 14.28 billion CNY, down 12.08% year-over-year [1]. - The gross margin for H1 2024 was 9.00%, a slight decrease of 0.03 percentage points year-over-year. The overseas business gross margin improved significantly to 7.33%, an increase of 2.35 percentage points year-over-year [1][6]. Business Segments - The infrastructure construction business saw a revenue decline of 6.76% year-over-year, primarily due to significant drops in road and municipal business revenues, which fell by 9.82% and 7.97% respectively [1]. - Emerging business segments, including water conservancy, clean energy, and ecological protection, have shown strong growth, with new contracts increasing by 32.1% year-over-year [2]. Future Outlook - The company has revised its revenue forecasts for 2024-2026, expecting revenues of 1,203.84 billion CNY, 1,288.11 billion CNY, and 1,365.39 billion CNY, with respective year-over-year growth rates of 4.7%, 7.0%, and 6.0% [6][7]. - The net profit forecasts for the same period are 30.90 billion CNY, 33.16 billion CNY, and 35.31 billion CNY, with expected year-over-year growth rates of -7.7%, 7.3%, and 6.5% [6][7].

Investment Rating - The report assigns a "Buy-A" rating to the company with a target price of 17.22 CNY based on a 14x PE for 2024 [4][7]. Core Insights - The company is recognized as a leading player in the domestic gaming industry, successfully navigating through multiple industry transformations and focusing on a strategy of "premiumization, diversification, and globalization" [2][7]. - The company has established a robust integrated research and operation system, enhancing its product offerings and operational efficiency through the application of AI and data analytics [19][24]. - The gaming market is witnessing significant growth in both overseas expansion and mini-games, which are expected to provide new growth momentum [3][36]. Summary by Sections Company Overview - The company has successfully transformed through four major industry changes, including the shift from web games to mobile games and the adoption of a buy-in advertising model [10][11]. - The founding team retains significant control, holding 34.77% of the shares, ensuring strategic continuity [12]. Financial Performance - The company reported a revenue of 92.32 billion CNY in the first half of 2024, a year-on-year increase of 18.96%, with a net profit of 12.6 billion CNY, up 3.15% [14]. - The gross margin has remained high, with a projected gross margin of 79.3% for 2024 [45]. Product Strategy - The company has adopted a "dual-core + diversified" product strategy, focusing on MMORPG and SLG genres while expanding into card games and simulation games [28][29]. - Successful titles include "Douluo Dalu: Soul Master Duel" and "Puzzles & Survival," contributing to a strong product matrix with multiple games generating over 100 million CNY in monthly revenue [29][38]. Future Growth Drivers - The company is positioned to benefit from the growing trend of game exports, with overseas revenue accounting for 35.1% of total income in 2023 [3][38]. - The mini-game market has shown rapid growth, with expectations for continued expansion in 2024, particularly in overseas markets [40][41]. Investment Outlook - The company is expected to achieve net profits of 27.36 billion CNY, 31.99 billion CNY, and 34.61 billion CNY for 2024, 2025, and 2026, respectively [7][43]. - The report emphasizes the company's strong potential in the mini-game sector and overseas markets as key areas for future growth [7][36].

Investment Rating - The report assigns a "Buy - A" investment rating to the company with a 6-month target price of HKD 32.77 [3][5]. Core Insights - The company, Green Bamboo Bio, has been deeply engaged in the biotechnology sector for over 20 years, focusing on the development of innovative human vaccines and therapeutic biological agents. It has successfully developed six vaccine products, with five already commercialized [1][10]. - The core product, LZ901, is a recombinant shingles vaccine that is expected to become the first of its kind approved for sale in China. The market for shingles vaccines in China is largely untapped, with a penetration rate of only 0.4% among individuals over 40, compared to over 40% in the U.S. [1][2][10]. - The company has a robust pipeline with seven products under development, including LZ901, K3 (a biosimilar to Humira), and K193 (a bispecific antibody) [1][5][10]. Summary by Sections Company Overview - Green Bamboo Bio was established in November 2001 and has a strong foundation in vaccine research and development. The founder, Kong Jian, has over 30 years of experience in the biopharmaceutical industry [1][10]. - The company has transitioned to a public company and is exploring new opportunities for growth through financing and partnerships [10]. Shingles Vaccine (LZ901) - LZ901 is positioned to capture a significant share of the domestic shingles vaccine market, which is projected to be a multi-billion market. The vaccine has shown excellent immunogenicity and low incidence of adverse reactions in clinical trials [1][2][10]. - The Phase III clinical trial for LZ901 commenced in September 2023, with plans to submit a Biologics License Application (BLA) to the National Medical Products Administration by January 2025 [1][2][10]. Other Products in Development - K3, a biosimilar to Humira, has completed Phase I clinical trials and is expected to enter Phase III trials in 2025. The company plans to price K3 significantly lower than existing biosimilars, enhancing its competitive edge [2][5][10]. - K193, a bispecific antibody for treating B-cell leukemia and lymphoma, is also in clinical development, with expectations to complete Phase I trials by 2025 [2][5][10]. Financial Projections and Valuation - The company anticipates revenues of HKD 0.02 billion in 2024, HKD 0.02 billion in 2025, and HKD 5.87 billion in 2026, with net profits projected to turn positive in 2026 [5][6][10]. - The report utilizes a Discounted Cash Flow (DCF) model for valuation, leading to the target price of HKD 32.77 [5][6][10]. Research and Development - The company maintains a high level of R&D expenditure, with approximately HKD 173 million in 2023, reflecting an 88.9% increase from 2022 due to the advancement of LZ901 [42][10]. - The R&D team is experienced, having previously developed several successful vaccines, and the company has established advanced technology platforms to support its product development [18][10].